Drugs & Targets Brukinsa receives FDA accelerated approval for marginal zone lymphoma September 24, 2021Vol.47 No.35
Drugs & Targets Tivdak granted FDA accelerated approval for recurrent or metastatic cervical cancer September 24, 2021Vol.47 No.35
Drugs & Targets Cancer-detecting software Paige Prostate authorized for marketing by FDA September 24, 2021Vol.47 No.35
Drugs & Targets FDA grants Fast Track designation to novel immunotherapy targeting solid tumors September 24, 2021Vol.47 No.35
Drugs & Targets Opdivo + chemo receives positive CHMP opinion for gastric, gastroesophageal junction, esophageal adenocarcinoma September 24, 2021Vol.47 No.35
Drugs & Targets Keytruda + chemo receives positive CHMP opinion in TNBC indication September 24, 2021Vol.47 No.35
Drugs & Targets Exkivity gets FDA accelerated approval for metastatic NSCLC with EGFR exon 20 insertion mutations September 17, 2021Vol.47 No.34
Drugs & Targets Active ingredient hypericin receives FDA orphan drug designation for T-cell lymphoma September 10, 2021Vol.47 No.33
Drugs & Targets Science 37, Foundation Medicine collaborate on interventional home-based clinical trials in oncology September 10, 2021Vol.47 No.33
Drugs & Targets FDA requires monitoring of long-term clinical outcomes for robotic surgery in breast cancer September 03, 2021Vol.47 No.32
